Opinion|Videos|April 3, 2025
VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression
Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Co-developed by NYU Langone and Dana-Farber, the Solavia platform integrates EHR workflows, decision support, and pathway tracking for APPs and PAs.
The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.
FDA approves camizestrant for ESR1-mutated advanced breast cancer, tasking oncology nurses with guiding patients through ctDNA-based surveillance.
Dana Delaski, MSN, FNP-BC, shares insights on how once-daily ruxolitinib, self-injected rusfertide, and givinostat will transform PV clinic workflows.
The FDA has approved oral iberdomide (Zenbexus) for relapsed/refractory multiple myeloma, offering patients a highly potent, accessible therapy.
Oncology clinicians must actively champion NCCN guidelines as a critical pillar of breast cancer survivorship care,
With daraxonrasib approved for metastatic pancreatic cancer, Yolanda Justal, APRN, discusses essential nursing workflows for home-based care.
Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Lutetium Lu 177 Dotatate for GEP-NET Care
2
Psycho-Oncology Care: Dr. Erik Bengtsen on Psilocybin & Patient Distress
3
Palliative and Psycho-Oncology Care: Dr. Ramy Sedhom on Patient Distress Signs
4
Nurse-Led Support Reduces Death Anxiety in Breast Cancer Care
5